论文部分内容阅读
目的:探讨应用前列地尔在治疗脑干梗死急性期对于白细胞介素-6(IL-6)、S100B蛋白表达的影响。方法:用双抗体夹心酶联免疫法测定60例急性脑干梗死患者血清IL-6、S100B蛋白水平变化,并根据神经功能缺损(NIHSS)评分、Barthel指数评分(BI)判断前列地尔治疗对于急性期脑干梗死疗效。结果:前列地尔组在治疗急性期脑干梗死第3天可以显著降低IL-6、S100B的表达,第14天时下降更为显著,同时可以显著降低(NIHSS)评分、提高BI评分,提高疗效。2组比较具有统计学差异(P<0.05)。结论:应用前列地尔可以显著降低IL-6、S100B的表达,改善脑干梗死的预后。
Objective: To investigate the effect of alprostadil on the expression of interleukin-6 (IL-6) and S100B in the treatment of acute brain stem infarction. Methods: Serum levels of IL-6 and S100B in 60 patients with acute brain stem infarction were measured by double antibody sandwich enzyme-linked immunosorbent assay. Alprostadil treatment was evaluated according to NIHSS score and Barthel index score (BI) Acute brain stem infarction efficacy. Results: The alprostadil group could significantly reduce the expression of IL-6 and S100B on the 3rd day after the acute cerebral infarction, and the decrease was more significant on the 14th day. At the same time, the NIHSS score, the BI score and the therapeutic effect were improved . The difference between the two groups was statistically significant (P <0.05). Conclusion: The application of alprostadil can significantly reduce the expression of IL-6, S100B and improve the prognosis of cerebral infarction.